Related Experiment Video
Updated: Jul 29, 2025

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach]
Stefania Angela Di Fusco1, Lorenzo Castello1, Gaetano Marino1
1U.O.C. Cardiologia Clinica e Riabilitativa, Presidio Ospedaliero San Filippo Neri - ASL Roma 1, Roma.
Abstract:
Pathophysiologic processes promoted by uric acid, including inflammation and oxidative stress, play a key role in the pathogenesis of several cardiovascular diseases. Furthermore, a number of epidemiological studies have shown an association between uric acid plasma levels and multiple cardiovascular risk factors. This ANMCO statement provides an update on available evidence regarding the association between elevated plasma uric acid levels and cardiovascular disease risk and the safety and efficacy of uric acid lowering agents (allopurinol and febuxostat) used in patients with urate crystal deposits. In addition, it summarizes practical indications for the use of these drugs in at-risk patients or in patients with cardiovascular disease.
More Related Videos
10:02Quantitative SERS Detection of Uric Acid via Formation of Precise Plasmonic Nanojunctions within Aggregates of Gold Nanoparticles and Cucurbit[n]uril
Published on: October 3, 2020
05:57Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Related Concept Videos
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Rheumatic Heart Disease III: Medical Management
Coronary Artery Disease I: Introduction
Cardiovascular Drugs: Classification based on Therapeutic Indications